Enhancing Lenalidomide Treatment in Renal-Impaired Transplant-Eligible NDMM Patients

Overview

The REMNANT study prospectively evaluated higher-than-label lenalidomide doses in transplant-eligible newly diagnosed multiple myeloma (TE-NDMM) patients with renal impairment (RI). Lenalidomide at 25 mg/day for eGFR ≥30 and 15 mg/day for eGFR <30 was well tolerated, showing promising renal recovery and overall response rates during induction therapy.

Background

Renal impairment is a defining and adverse prognostic factor in multiple myeloma, significantly reducing overall survival. Rapid renal recovery, linked to early reduction of serum free light chains, is a critical treatment goal. Lenalidomide, primarily renally excreted, requires dose adjustments in RI patients per current guidelines, but recent data suggest higher doses may be safe and potentially more effective in this population.

Data Highlights

Key Findings

• Lenalidomide doses higher than current label recommendations were safely administered in TE-NDMM patients with renal impairment.
• Patients with eGFR ≥30 mL/min/1.73m2 received 25 mg/day, while those with eGFR <30 received 15 mg/day during induction.
• Renal response was assessed using IMWG criteria, showing encouraging recovery rates across renal function groups after four cycles of VRd induction.
• Adverse events related to lenalidomide were monitored, with only grade ≥2 events requiring intervention reported.
• The study supports that higher lenalidomide dosing may facilitate faster serum free light chain reduction and improved renal outcomes.

Clinical Implications

These findings suggest that lenalidomide dosing in TE-NDMM patients with renal impairment can be safely optimized above current conservative recommendations, potentially improving renal recovery and overall treatment efficacy. Clinicians should consider individualized dosing strategies based on renal function while monitoring for adverse events. This approach may enhance early treatment response and survival outcomes in this high-risk population.

Conclusion

The REMNANT study provides prospective evidence supporting the safety and efficacy of higher-dose lenalidomide in transplant-eligible NDMM patients with renal impairment, highlighting a potential paradigm shift in dosing strategies to improve renal and overall outcomes.

References

1. REMNANT Study Protocol and Results, 2024 -- Enhancing Lenalidomide Treatment in Renal Impairment
2. Chen et al., 2011 -- Pharmacokinetics of Lenalidomide in Renal Impairment
3. Mayo Clinic PrE1003 Trial, 2020 -- Lenalidomide Dosing in Renal Impairment
4. IMWG Renal Response Criteria, 2016 -- Renal Outcomes in Multiple Myeloma